Global Single-Cell Genome Sequencing Market

MARKET SCOPE:

The global Single-Cell Genome Sequencing market is projected to grow significantly, registering a CAGR of 15.1% during the forecast period (2024 – 2032).

Single-cell genome sequencing represents an advanced molecular biology technique designed to sequence the DNA content of individual cells. In contrast to traditional genome sequencing approaches, which involve analyzing a population of cells collectively and potentially obscuring genetic variations among individual cells, single-cell genome sequencing offers a comprehensive perspective of the genomic landscape within each individual cell. The process initiates with the isolation of individual cells from a sample, such as tissues or cultured cells, utilizing various methods like microfluidics or laser capture microdissection. Following isolation, the individual cell undergoes lysis, leading to the breakdown of the cell membrane and the release of its genomic DNA. Given the minute quantity of DNA present in a single cell, techniques such as whole-genome amplification are implemented to generate sufficient material for subsequent sequencing endeavors.

MARKET OVERVIEW:

Driver: The surging cancer incidence is expected to boost the market growth.

The anticipated rise in cancer prevalence is poised to drive the expansion of the single-cell genome sequencing market. Cancer, encompassing a diverse range of diseases characterized by uncontrolled cell growth, results from genetic alterations affecting genes responsible for cell division and normal cellular functions. The genetic changes occurring in individual cancer cells can be unveiled through single-cell genome sequencing, providing valuable insights into the intricacies of the disease. For instance, as reported by the American Cancer Society in January 2023, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were recorded in the United States in 2022. Projections indicate that by 2040, there could be around 27.5 million new cancer cases and 16.3 million cancer-related deaths. Consequently, the escalating prevalence of cancer is anticipated to act as a significant catalyst for the growth of the single-cell genome sequencing market.

Opportunities: Exponential growth in genomic data is expected to pave the way for market growth in the upcoming years.

The substantial expansion in genomic data is a significant factor contributing to the anticipated growth of the single-cell genome sequencing market. Genomic data encompasses information related to the structure and functionality of an organism's genome. The exponential surge in genomic data, primarily propelled by single-cell sequencing, presents opportunities for enhanced data analysis, interpretation, and the development of advanced bioinformatics tools, thereby fostering the market's expansion. As per data released in 2022 by the National Human Genome Research Institute (NHGRI), a US-based government institute dedicated to human genome research, it is projected that genomic data will range from 2 to 40 exabytes within the next decade. This rapid growth in genomic data is poised to be a driving force behind the continued expansion of the single-cell genome sequencing market.

COVID IMPACT:

The COVID-19 pandemic has had a favorable impact on the examined market, with several research studies shedding light on the influence of COVID-19 on single-cell sequencing. One notable example is a research publication from September 2020 titled 'Single-cell Landscape of Immunological Responses in Patients with COVID-19,' which explored the relationship between disease severity and the host immune response in individuals with COVID-19 caused by SARS-CoV-2 infection. The findings revealed a robust interferon-α response and a general acute inflammatory response across various cell types in COVID-19 patients through single-cell sequencing. This study and others like it provide valuable insights into the application of single-cell sequencing in understanding COVID-19. Similarly, a research study in February 2022, titled 'Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+ Monocytes and Memory CD8+ T Cells Involved in Severe COVID-19,' highlighted a significant genetics-modulated immunological shift between mild and severe infections. The study identified elevated expression of genetics-risk genes, increased inflammatory cytokines, and alterations in functional immune cell subsets contributing to disease severity. These investigations offer novel perspectives on deciphering the host genetic determinants influencing peripheral immune cells in severe COVID-19, contributing to an increased understanding of the virus and thereby fostering future market growth.

SEGMENTATION ANALYSIS:

The PCR segment is anticipated to grow significantly during the forecast period.

Factors such as initiatives undertaken by key market players, including product launches and collaborations, are anticipated to contribute significantly to market growth in the forecast period. The growth of the market segment is propelled by the introduction of new products. For example, in June 2020, Stilla Technologies unveiled 'the six-color Prism,' one of the world's first six-color digital PCR instruments. This system finds versatile applications in oncology, infectious disease, gene therapy, disease monitoring, and food testing. Similarly, in July 2022, Bio-Rad introduced the CFX Opus Deepwell real-time PCR detection system, designed to support research in developing nucleic acid detection assays.

Furthermore, strategic collaborations among industry players are enhancing market segment growth and strengthening global competitiveness. In October 2021, PerkinElmer and Honeycomb Biotechnologies jointly announced the launch of the groundbreaking HIVE scRNAseq Solution for single-cell isolation and analysis. The innovative HIVE solution utilizes a portable, handheld device for the capture, storage, and RNA-Seq library preparation of various cell types, including delicate ones like granulocytes, nephrons, hepatocytes, and neurons. This solution, requiring no specialized instrumentation, broadens opportunities for laboratories engaged in basic, translational, clinical, and preclinical research. Such collaborative efforts and product launches are expected to drive advancements and foster growth within the market segment.

The cancer is anticipated to grow significantly during the forecast period.

Cancer stands as a prominent non-communicable disease, ranking as the second leading cause of death, according to the World Health Organization. In a 2021 report by the International Agency for Research on Cancer, over 18 million new cancer cases were reported, resulting in approximately 9 million deaths, with more than 35 million people living with cancer globally. The introduction of innovative cancer therapies, including personalized medicine such as immuno-oncology, is anticipated to drive the adoption of single-cell genomic sequencing. This advancement facilitates evolving research efforts to scrutinize cellular-level changes in cancer cells, contributing to a deeper understanding of the disease and potential improvements in treatment strategies.

REGIONAL ANALYSIS:

The North American region is set to witness significant growth during the forecast period.

Factors such as increasing disease prevalence and strategic actions like product launches and expansions by key market players are poised to propel market growth in the region. The United States, for instance, is witnessing a notable rise in cancer cases, as indicated by the Cancer Statistics 2021 published in the American Cancer Society Journal. With an estimated 1.9 million new cancer cases and 608,570 cancer-related deaths reported, the market is expected to experience significant growth. Similarly, data from Globocan 2020 revealed that the United States recorded an estimated 195,449 new cancer cases in 2020, and this number is projected to increase during the forecast period, further contributing to market expansion.

Moreover, the introduction of new products based on single-cell sequencing is anticipated to play a pivotal role in driving market growth. For instance, in September 2020, Roche obtained approval from the United States Food and Drug Administration (FDA) for the Cobas HIV-1/HIV-2 Qualitative Test, designed for use on the fully automated Cobas 6800/8800 Systems in the US. This test facilitates healthcare professionals in confirming HIV diagnosis with a single test while distinguishing between HIV-1 and HIV-2, a critical differentiation for identifying appropriate treatment options. Additionally, in October 2021, Takara Bio USA, Inc., a wholly-owned subsidiary of Takara Bio Inc., launched the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System. This automated single-cell RNA-seq technology enables scientists to simultaneously collect full-length transcriptome data from over 1,500 single cells, including complex and delicate adult cardiomyocytes, further contributing to substantial market growth.

COMPETITIVE ANALYSIS

The global Single-Cell Genome Sequencing market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

Sengenics

• In March 2022, Sengenics had officially introduced the i-Ome Protein Array Kit for commercial use. This kit features slide-based, high-density protein microarrays that include over 1600 immobilized, full-length, and properly folded human proteins.

Bio-Rad Laboratories

10x Genomics

Novogene

Fluidigm

BGI

Illumina, Inc.

Oxford Nanopore Technologies

Pacific Biosciences

Thermo Fisher Scientific, Inc.

QIAGEN

F. Hoffmann-La-Roche Ltd.

SCOPE OF THE REPORT

By Type

• Gene Therapy
• RNA-based Therapies

By Technology

• Process Development and Optimization
• Manufacturing Services
• Analytical and Quality Control Services
• Others

By Disease Area

• Oncology
• Genetic Disorders
• Infectious Diseases
• Others

By End Users

• Pharmaceutical Companies
• Government & Academic Research Institutes
• Biotech Companies

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

KEY REASONS TO PURCHASE THIS REPORT

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Single-Cell Genome Sequencing market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Single-Cell Genome Sequencing submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032. Show more